C9orf142 transcriptionally activates MTBP to drive progression and resistance to CDK4/6 inhibitor in triple-negative breast cancer.

Li LiaoLing DengYin-Ling ZhangShao-Ying YangLisa AndrianiShu-Yuan HuFang-Lin ZhangZhi-Min ShaoDa-Qiang Li

Published in: Clinical and translational medicine (2023)

Together, these findings unveil a previously unrecognized effect of C9orf142 in TNBC progression and responsiveness to CDK4/6 inhibitor, and emphasize C9orf142 as a promising intervention target for TNBC treatment.

Keyphrases

cell cycle
randomized controlled trial
cell proliferation
smoking cessation